T1	Condition 6 22	hypersensitivity
T2	Drug 26 29	egg
T3	Drug 31 47	soybean proteins
T4	Drug 49 64	peanut proteins
T5	Drug 66 70	corn
T6	Drug 74 87	corn products
T7	Drug 106 123	active substances
T8	Drug 127 137	excipients
*	OR T5 T6 T7 T8 T4 T3 T2
T9	Scope 26 137	egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients
R1	Has_scope Arg1:T1 Arg2:T9	
T10	Condition 146 160	hyperlipidemia
T11	Qualifier 139 145	Severe
R2	Has_qualifier Arg1:T10 Arg2:T11	
T12	Qualifier 164 170	severe
T13	Condition 171 200	disorders of lipid metabolism
R3	Has_qualifier Arg1:T13 Arg2:T12	
T14	Condition 218 238	hypertriglyceridemia
T15	Measurement 240 272	serum triglyceride concentration
T16	Value 273 284	>1,000 g/dL
R4	Has_value Arg1:T15 Arg2:T16	
R5	Subsumes Arg1:T14 Arg2:T15	
*	OR T10 T13 T14
T17	Condition 288 326	Inborn errors of amino acid metabolism
T18	Condition 328 355	Cardiopulmonary instability
T19	Condition 367 382	pulmonary edema
T20	Condition 384 405	cardiac insufficiency
T21	Condition 407 428	myocardial infarction
T22	Condition 430 438	acidosis
T23	Condition 443 466	hemodynamic instability
T24	Qualifier 489 508	vasopressor support
T25	Qualifier 477 488	significant
R6	Has_qualifier Arg1:T24 Arg2:T25	
R7	Has_qualifier Arg1:T23 Arg2:T24	
T26	Drug 489 500	vasopressor
*	OR T22 T23 T21 T20 T19
T27	Scope 367 508	pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support
R8	Subsumes Arg1:T18 Arg2:T27	
T28	Condition 511 534	Hemophagocytic syndrome
T29	Procedure 537 539	PN
T30	Temporal 540 584	in the last 7 days prior to study enrollment
T31	Reference_point 568 584	study enrollment
R9	Has_index Arg1:T30 Arg2:T31	
R10	Has_temporal Arg1:T29 Arg2:T30	
T32	Procedure 596 606	chronic PN
T33	Temporal 607 625	before study start
T34	Reference_point 614 625	study start
R11	Has_index Arg1:T33 Arg2:T34	
R12	Has_temporal Arg1:T32 Arg2:T33	
T35	Measurement 627 640	Liver enzymes
T36	Measurement 649 652	AST
T37	Measurement 654 657	ALT
T38	Measurement 659 663	GGPT
T39	Measurement 669 685	direct bilirubin
T40	Value 686 727	exceeding 2 x upper limit of normal range
*	OR T36 T37 T38
T41	Scope 649 663	AST, ALT, GGPT
R13	Subsumes Arg1:T35 Arg2:T41	
*	OR T35 T39
T42	Scope 627 685	Liver enzymes (either AST, ALT, GGPT), or direct bilirubin
R14	Has_value Arg1:T42 Arg2:T40	
T43	Value 729 751	Pathologically altered
T44	Measurement 752 782	level of any serum electrolyte
T45	Measurement 784 790	sodium
T46	Measurement 792 801	potassium
T47	Measurement 803 812	magnesium
T48	Measurement 814 821	calcium
T49	Measurement 823 831	chloride
T50	Measurement 833 842	phosphate
*	OR T45 T46 T47 T48 T49 T50
T51	Scope 784 842	sodium, potassium, magnesium, calcium, chloride, phosphate
R15	Subsumes Arg1:T44 Arg2:T51	
R16	Has_value Arg1:T44 Arg2:T43	
T52	Non-representable 844 898	unless corrected prior to the start of study treatment
T53	Value 900 922	Pathologically altered
T54	Measurement 923 931	blood pH
T55	Measurement 936 953	oxygen saturation
T56	Measurement 958 972	carbon dioxide
*	OR T55 T56 T54
T57	Scope 923 972	blood pH, or oxygen saturation, or carbon dioxide
R17	Has_value Arg1:T57 Arg2:T53	
T58	Condition 1042 1051	lactation
T59	Condition 1029 1038	Pregnancy
*	OR T59 T58
T60	Competing_trial 1053 1092	Participation in another clinical study
